 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C29H25N3 |
| Molar mass | 415.540 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SoRI-20041 is an "antagonist-like"allosteric modulator ofamphetamine-induceddopamine release[1] (in contrast to the related research chemicalsSoRI-9804 andSoRI-20040, which are "agonist-like").[1] SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in thedopamine transporter (possibly showing how inward and outward transport represent distinct operational modes of DAT); it produces the same effects as SoRI-20040 and SoRI-9804 in uptake assays and binding assays, inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like 'agonists' of the series do.[1]
This suggests the possibility of simultaneous action and increase of indirect-agonism through the dual action of DRA andDRIefficacy existing together. This increases the inhibition of re-uptake at synaptic dopamine concentrations without interfering in the flow of release of dopamine from amphetaminergic phosphorylation at the affected transporter. This overcomes the obstacle of a compromised binding site that would be rendered unusable through the action of amphetamine. Conventional dopamine re-uptake inhibitors (such ascocaine ormethylphenidate) would otherwise ineffectively target such a site on each specific transporter so affected by amphetamine, making this an example of a DRI that does not have a mutually exclusive functionality against DRA action at individual instances of DAT.
